K.J. Harrison & Partners Inc Sells 25,500 Shares of Pfizer Inc. $PFE

K.J. Harrison & Partners Inc trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 21.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 94,003 shares of the biopharmaceutical company’s stock after selling 25,500 shares during the period. K.J. Harrison & Partners Inc’s holdings in Pfizer were worth $2,640,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Evolution Wealth Management Inc. boosted its stake in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares in the last quarter. Horizon Financial Services LLC lifted its holdings in Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares during the period. Godfrey Financial Associates Inc. bought a new stake in Pfizer during the 4th quarter valued at $26,000. YANKCOM Partnership purchased a new position in shares of Pfizer in the 4th quarter valued at $28,000. Finally, HFM Investment Advisors LLC raised its position in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 427 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent research reports. HSBC raised their price objective on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. CICC Research initiated coverage on shares of Pfizer in a report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price target on the stock. Citigroup lifted their price objective on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Morgan Stanley increased their target price on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $28.82.

Pfizer Stock Down 0.1%

Pfizer stock opened at $24.29 on Friday. The business’s 50-day simple moving average is $25.63 and its two-hundred day simple moving average is $26.23. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The company has a market cap of $138.45 billion, a PE ratio of 18.54 and a beta of 0.35. Pfizer Inc. has a fifty-two week low of $23.11 and a fifty-two week high of $28.75.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same quarter in the prior year, the firm earned $0.92 earnings per share. Pfizer’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. Pfizer’s payout ratio is currently 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.